• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    HighCape Capital Acquisition Corp. filed SEC Form 8-K: Leadership Update

    7/6/21 6:52:38 AM ET
    $CAPA
    Business Services
    Finance
    Get the next $CAPA alert in real time by email
    8-K 1 tm2121264d1_8k.htm FORM 8-K

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 29, 2021

     

     

    QUANTUM-SI INCORPORATED

    (Exact name of registrant as specified in its charter)

     

     

    Delaware 001-39486 85-1388175
    (State or other jurisdiction of
    incorporation)
    (Commission File Number) (IRS Employer
    Identification No.)
         
    530 Old Whitfield Street
    Guilford, Connecticut
    (Address of principal executive offices)
      06437
    (Zip Code)

     

    Registrant’s telephone number, including area code: (203) 458-7100

     

    N/A

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on
    which registered
    Class A common stock, par value $0.0001 per share   QSI   The Nasdaq Stock Market LLC
    Redeemable warrants, each whole warrant exercisable for one share of Class A common stock, each at an exercise price of $11.50 per share   QSIAW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company          x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On June 29, 2021, the Board of Directors (the “Board”) of Quantum-Si Incorporated (the “Company”) adopted the Quantum-Si Incorporated Executive Severance Plan (the “Severance Plan”). Current participants in the Severance Plan include the Company’s Chief Executive Officer and its other executive officers.

     

    Under the Severance Plan, if the Company terminates a participant’s employment without cause (as defined in the Severance Plan) at any time other than during the twelve (12) month period following a change in control (as such term is defined in the Severance Plan) (the “Change in Control Period”), then the participant is eligible to receive the following benefits:

     

    ·Severance payable in the form of salary continuation or a lump sum payment. The severance amount is equal to participant’s then-current base salary times a multiplier determined based on the participant’s title or role with the Company.

     

    ·The portion of any outstanding unvested equity award that would vest on an annual cliff vesting date in accordance with the terms of the award during the three months following the participant’s termination date will become fully vested as of the date the termination of such participant’s employment becomes effective. If the Chief Executive Officer is terminated without cause or resigns with good reason (as defined in the Severance Plan) prior to January 7, 2022, his equity award that is scheduled to vest in accordance with the terms of the award as to 25% of the award on January 7, 2022 will become vested as to 25% of the award as of the date the termination of the Chief Executive Officer’s employment becomes effective.

     

    ·The Company will pay for company contribution for continuation coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”) during the severance period.

     

    Under the Severance Plan, if the Company terminates a participant’s employment without cause or a participant resigns for good reason, during the Change in Control Period, then the participant is eligible to receive the following benefits:

     

    ·Severance payable in a single lump sum. The severance amount is equal to participant’s then-current base salary and then-current target annual bonus opportunity, times a change in control multiplier determined based on the participant’s title or role with the Company.

     

    ·The Company will pay for company contribution for continuation coverage under COBRA during the severance period.

     

    ·Any outstanding unvested equity awards held by the participant under any then-current outstanding equity incentive plan(s) will become fully vested as of the date the termination of such participant’s employment becomes effective.

     

    A participant’s rights to any severance benefits under the Severance Plan are conditioned upon the participant executing and not revoking a valid separation and general release of claims agreement in a form provided by the Company.

     

    The foregoing summary of the Severance Plan is qualified in its entirety by reference to the full text of the Severance Plan, a copy of which is attached as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference.

     

    In addition, on June 29, 2021, the Board approved an increase in annual base salary effective as of July 1, 2021 for John Stark, the Company’s Chief Executive Officer, from $350,000 to $500,000. In addition, the Board approved an increase to Mr. Stark’s target annual performance bonus payment commencing with 2021 performance from 60% to 100% of his base salary. Bonus payments will be based upon the achievement of corporate and/or individual performance goals as determined by the Board or Compensation Committee of the Board.

     

    Item 9.01Financial Statements and Exhibits.

     

    (d)Exhibits.

     

    Exhibit
    No.
      Description
         
    10.1   Quantum-Si Incorporated Executive Severance Plan

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      QUANTUM-SI INCORPORATED
         
      By: /s/ John Stark
      Name: John Stark
      Title: Chief Executive Officer

     

    Date:July 6, 2021

     

     

    Get the next $CAPA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CAPA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CAPA
    SEC Filings

    See more
    • HighCape Capital Acquisition Corp. filed SEC Form 8-K: Leadership Update

      8-K - Quantum-Si Inc (0001816431) (Filer)

      7/6/21 6:52:38 AM ET
      $CAPA
      Business Services
      Finance
    • SEC Form S-1 filed by HighCape Capital Acquisition Corp.

      S-1 - Quantum-Si Inc (0001816431) (Filer)

      7/2/21 5:00:18 PM ET
      $CAPA
      Business Services
      Finance
    • HighCape Capital Acquisition Corp. filed SEC Form 8-K: Leadership Update

      8-K - Quantum-Si Inc (0001816431) (Filer)

      6/25/21 4:37:54 PM ET
      $CAPA
      Business Services
      Finance

    $CAPA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Issuer Direct Announces New Board of Directors to Support Next Chapter of Growth

      RALEIGH, NC / ACCESSWIRE / July 1, 2024 / Issuer Direct Corporation (NYSE:ISDR), an industry-leading communications company, today announced it has appointed Wes Pollard and Joe Staples as new independent members of its Board of Directors."We are excited to welcome Wes and Joe to the Issuer Direct Board of Directors," said CEO Brian Balbirnie. "We believe their respective skillsets are an ideal fit for us as we pursue our strategic vision to be a leading provider of media and communications software to the PR (Public Relations) and IR (Investor Relations) industry. We are confident they will be valuable additions to our company as we continue to optimize our business and work to maximize val

      7/1/24 10:45:00 AM ET
      $ISDR
      $CAPA
      Publishing
      Consumer Discretionary
      Business Services
      Finance
    • Quantum-Si Announces Expansion of Early Access Program for the Platinum™ Single Molecule Protein Sequencing Platform

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si," "QSI" or the "Company"), a life science tools company commercializing a unique protein sequencing platform, announced today that they have expanded their Platinum early access program to ten sites, with participation from leading academic centers and key industry partners. The early access program introduces the Platinum single molecule sequencing system to key opinion leaders across the globe, for both expansion and development of applications and workflows. "The Company is experiencing tremendous momentum and demand for participation in our early access program to analyze previously unapproachable levels of biological understanding of t

      10/19/21 4:15:00 PM ET
      $CAPA
      $QSI
      Business Services
      Finance
      Industrial Machinery/Components
      Industrials
    • Quantum-Si Incorporated to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

      Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si" or the "Company"), a company pioneering next-generation semiconductor chip-based proteomics, today announced its participation in the Cantor Fitzgerald Virtual Global Healthcare Conference which takes place September 27-30, 2021. John Stark, Quantum-Si's Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will participate in a virtual fireside chat on Wednesday, September 29, at 1:20 – 1:50 pm EDT. Please visit the Investor Relations section of the Quantum-Si website here to view the Company's most recent corporate presentation. About Quantum-Si Incorporated Founded by Dr. Jonathan Rothberg in 2013, Quantum-Si is focus

      9/21/21 4:15:00 PM ET
      $CAPA
      $QSI
      Business Services
      Finance
      Industrial Machinery/Components
      Industrials

    $CAPA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: RAKIN KEVIN was granted 1,921,512 units of Class A Common Stock

      4 - Quantum-Si Inc (0001816431) (Issuer)

      6/15/21 5:27:21 PM ET
      $CAPA
      Business Services
      Finance
    • SEC Form 4: ROTHBERG JONATHAN M was granted 17,213,479 units of Class A Common Stock and was granted 19,937,500 units of Class B Common Stock

      4 - Quantum-Si Inc (0001816431) (Issuer)

      6/14/21 6:56:10 PM ET
      $CAPA
      Business Services
      Finance
    • SEC Form 4: Makes Brigid was granted 20,512 units of Class A Common Stock

      4 - Quantum-Si Inc (0001816431) (Issuer)

      6/14/21 6:56:44 PM ET
      $CAPA
      Business Services
      Finance

    $CAPA
    Financials

    Live finance-specific insights

    See more

    $CAPA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Quantum-Si Reports Second Quarter 2021 Financial Results

      Quantum-Si Solidifies Financial Strength and Continues Systematic Commercialization Strategy Quantum-Si Incorporated (NASDAQ:QSI) ("Quantum-Si" or the "Company"), a company pioneering next-generation semiconductor chip-based proteomics, today announced financial results for the quarter ended June 30, 2021 and provided a business update. John Stark, Quantum-Si's Chief Executive Officer, and Claudia Drayton, Quantum-Si's Chief Financial Officer, will host a call today at 4:30 pm EDT to review the Company's results. Recent Highlights: Completed the business combination with HighCape Capital Acquisition Corp. ("HighCape"), adding over $511 million in cash to the balance sheet. Successfull

      8/16/21 4:05:00 PM ET
      $CAPA
      $QSI
      Business Services
      Finance
      Industrial Machinery/Components
      Industrials
    • Quantum-Si to Report Second Quarter 2021 Financial Results on August 16, 2021

      Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, today announced that it has rescheduled its conference call to report second quarter 2021 financial results to August 16, 2021, after market close. John Stark, Chief Executive Officer, and Claudia Drayton, Chief Financial Officer, will host a conference call and webcast at 4:30 p.m. ET on August 16, 2021, to discuss second quarter 2021 financial results and provide a business update. The conference call will be broadcast live in listen-only mode via a webcast on Quantum-Si's Investor Relations website at Events & Presentations. Individuals interested in listening to the conference call on y

      8/11/21 7:00:00 AM ET
      $CAPA
      $QSI
      Business Services
      Finance
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13D filed by HighCape Capital Acquisition Corp.

      SC 13D - Quantum-Si Inc (0001816431) (Subject)

      6/21/21 5:20:40 PM ET
      $CAPA
      Business Services
      Finance
    • SEC Form SC 13D filed by HighCape Capital Acquisition Corp.

      SC 13D - Quantum-Si Inc (0001816431) (Subject)

      6/21/21 3:37:21 PM ET
      $CAPA
      Business Services
      Finance
    • SEC Form SC 13D/A filed by HighCape Capital Acquisition Corp. (Amendment)

      SC 13D/A - Quantum-Si Inc (0001816431) (Subject)

      6/14/21 5:18:16 PM ET
      $CAPA
      Business Services
      Finance

    $CAPA
    Leadership Updates

    Live Leadership Updates

    See more
    • Quantum-Si Strengthens Board of Directors With Two Key Appointments

      Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today the appointment of Marijn Dekkers, Ph.D. and Ruth Fattori to its Board of Directors. Both Dr. Dekkers and Ms. Fattori have agreed to continue to serve on the Board of Directors of the combined company subsequent to the closing of the previously announced business combination between Quantum-Si and HighCape Capital Acquisition Corp (NASDAQ:CAPA). "We are positioning Quantum-Si to have the best chance of delivering on the promise of next-generation proteomics by continuing to enhance our leadership team and board of directors, including the addition of Dr. Marijn Dekkers, former

      5/6/21 8:00:00 AM ET
      $CAPA
      Business Services
      Finance
    • Quantum-Si Appoints Dr. Michael Mina as Chief Medical Advisor

      Quantum-Si Incorporated, a company pioneering next-generation semiconductor chip-based proteomics, announced today the appointment of Michael Mina, M.D., Ph.D., Assistant Professor of Epidemiology, Immunology, Infectious Diseases and Pathology at the Harvard T.H. Chan School of Public Health and Harvard Medical School, as Chief Medical Advisor for the company. "As we create the next generation of protein sequencing and proteomics to transform how we study and diagnose disease, moving from the analog to the digital world and allowing a level of sensitivity, precision and understanding never before possible, Dr. Mina's expertise will be invaluable in guiding Quantum-Si's application efforts,

      4/29/21 8:00:00 AM ET
      $CAPA
      Business Services
      Finance